Clinical Trial Update: This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye [Phase 4]

View source ↗

Summary

Phase 4 open-label prospective study at a single center to evaluate the effect of Lifitegrast (Xiidra) 5% ophthalmic solution on tear film biomarkers in dry eye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease
• Ocular Surface Disease

Drugs mentioned

• Xiidra (Lifitegrast)

Snippet

Sponsor: Pittsburgh Research Institute | Conditions: Ocular Surface Disease, Dry Eye Syndrome (DES) | Phase 4 | Status: NOT_YET_RECRUITING